Psychedelic-assisted psychotherapies are generating excitement in psychiatry and the media, but they remain investigational and not yet approved for general clinical use. This review helps psychiatrists navigate the complexities of the field, covering research equipoise, informed consent, patient vulnerability, equity and access, differences between clinical and nonclinical uses, and psychedelic self-enhancement. The unique altered states of consciousness and patient vulnerability require careful ethical consideration to minimize pitfalls. The goal is to equip psychiatrists to use psychedelic psychotherapy ethically and effectively as it moves toward regulatory approval.
For patients with mood disorders or PTSD who have not responded to multiple treatments, few options exist. After decades of federal restrictions on psychedelic research, recent studies have re-examined compounds like MDMA and psilocybin. These investigations involve safe administration in controlled settings, preceded by hours of participant preparation and followed by integration sessions. The improvements participants experience appear linked to profound shifts in perspective, distinct from those achieved with current standard care. Studies have addressed treatment-resistant depression, end-of-life despair, and PTSD. Psychedelic psychotherapy, combining biological therapy with psychotherapy, may transform mental health care.